Fecal microbiota transplantation
Authors:
Igor Šturdík; Tibor Hlavatý; Juraj Payer
Authors‘ workplace:
V. interná klinika LF UK a UN Bratislava, pracovisko Nemocnica Ružinov, Slovenská republika
Published in:
Vnitř Lék 2016; 62(2): 147-151
Category:
Reviews
Overview
Fecal microbiota transplantation (FMT) is a therapeutic method, in which the fecal microflora from healthy donors is transmitted to the patient to restore the healthy microbial composition of the gut. In the recent years, there is a growing interest in the therapeutic potential of FMT in various diseases. The standard FMT protocols do not exist. Procedures of FMT vary in several aspects such as donor selection, preparation of fecal material, preparation of the recipient and administration way. FMT appears to be the most successful in the treatment of recurrent Clostridium difficile infection (CDI), randomized controlled studies reported 90 % success rate. There is a limited evidence for FMT as a treatment of ulcerative colitis. FMT has been also studied as treatment of diseases with impaired gut microbiota, such as cardiovascular, autoimmune and metabolic diseases. Many unanswered questions with regard to FMT remain and further research is needed.
Key words:
Clostridium difficile – fecal microbiota transplantation – gut microbiota – inflammatory bowel diseases
Sources
1. Eiseman B, Silen W, Bascom GS et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958; 44(5): 854–859.
2. Di Bella S, Drapeau C, García-Almodóvar E et al. Fecal microbiota transplantation: the state of the art. Infect Dis Rep 2013; 5(2): e13. Dostupné z DOI: http://dx.doi.org/10.4081/idr.2013.e13.
3. van Nood E, Vrieze A, Nieuwdorp M et al. Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile. N Engl J Med 2013; 368(5): 407–415.
4. Gough E, Shaikh H, Manges AR. Systematic Review of Intestinal Microbiota Transplantation (Fecal Bacteriotherapy) for Recurrent Clostridium difficile Infection. Clin Infect Dis 2011; 53(10): 994–1002.
5. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003; 36(5): 580–585.
6. Bakken JS, Borody T, Brandt LJ et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011; 9(12): 1044–1049.
7. Kelly CR, de Leon L, Jasutkar N. Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results. J Clin Gastroenterol 2012; 46(2): 145–149.
8. Landy J, Al-Hassi HO, McLaughlin SD et al. Review article: faecal transplantation therapy for gastrointestinal disease. Aliment Pharmacol Ther 2011; 34(4): 409–415.
9. Mellow MH, Kanatzar A. Colonoscopic fecal bacteriotherapy in the treatment of recurrent Clostridium difficile infection – results and follow-up. J Okla State Med Assoc 2011; 104(3): 89–91.
10. Rohlke F, Surawicz CM, Stollman N. Fecal flora reconstitution for recurrent Clostridium difficile infection: results and methodology. J Clin Gastroenterol 2010; 44(8): 567–570.
11. Borody TJ, Paramsothy S, Agrawal G. Fecal Microbiota Transplantation: Indications, Methods, Evidence, and Future Directions. Curr Gastroenterol Rep 2013; 15(8): 337.
12. Satokari R, Fuentes S, Mattila E et al. Fecal Transplantation Treatment of Antibiotic-Induced, Noninfectious Colitis and Long-Term Microbiota Follow-Up. Case Rep Med 2014; 2014: 913867. Dostupné z DOI: http://dx.doi.org/10.1155/2014/913867.
13. Gustafsson A, Berstad A, Lund-Tonnesen S et al. The effect of faecal enema on five microflora-associated characteristics in patients with antibiotic-associated diarrhoea. Scand J Gastroenterol 1999; 34(6): 580–586.
14. Gustafsson A, Lund-Tonnesen S, Berstad A et al. Faecal short-chain fatty acids in patients with antibiotic-associated diarrhoea, before and after faecal enema treatment. Scand J Gastroenterol 1998; 33(7): 721–727.
15. Hamilton MJ, Weingarden AR, Sadowsky MJ et al. Standardized Frozen Preparation for Transplantation of Fecal Microbiota for Recurrent Clostridium difficile Infection. Am J Gastroenterol 2012; 107(5): 761–767.
16. Anderson JL, Edney RJ, Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther 2012; 36(6): 503–516.
17. Angelberger S, Reinisch W, Makristathis A et al. Temporal Bacterial Community Dynamics Vary Among Ulcerative Colitis Patients after Fecal Microbiota Transplantation. Am J Gastroenterol 2013; 108(10): 1620–1630.
18. Colman RJ, Rubin DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis 2014; 8(12): 1569–1581.
19. Quera R, Espinoza R, Estay C et al. Bacteremia as an adverse event of fecal microbiota transplantation in a patient with Crohn’s disease and recurrent Clostridium difficile infection. J Crohns Colitis 2014; 8(3): 252–253.
20. Kunde S, Pham A, Bonczyk S et al. Safety, Tolerability, and Clinical Response After Fecal Transplantation in Children and Young Adults With Ulcerative Colitis. J Pediatr Gastroenterol Nutr 2013; 56(6): 597–601.
21. Schwartz M, Gluck M, Koon S Norovirus gastroenteritis after fecal microbiota transplantation for treatment of Clostridium difficile infection despite asymptomatic donors and lack of sick contacts. Am J Gastroenterol 2013; 108(8): 1367.
22. Brandt LJ, Aroniadis OC, Mellow M et al. Long-Term Follow-Up of Colonoscopic Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection. Am J Gastroenterol 2012; 107(7): 1079–1087.
23. Kelly CR, de Leon L, Jasutkar N. Fecal Microbiota Transplantation for Relapsing Clostridium difficile Infection in 26 Patients. J Clin Gastroenterol 2012; 46(2): 145–149.
24. Smith MB, Kelly C, Alm EJ. Policy: How to regulate faecal transplants. Nature 2014; 506(7488): 290–291.
25. Vejmelka J, Kohout P, Koten J et al. Fekální bakterioterapie a nové cesty v léčbě klostridiové střevní infekce. Prakt Lék 2014; 94(4): 195–200.
26. Polak P, Freibergerová M, Juránková J et al. První zkušenosti s fekální bakterioterapií v léčbě relabující pseudomembranózní kolitidy způsobené Clostridium difficile. Klin Mikrobiol Inf Lék 2011; 17(6): 214–217.
27. Sartor RB. Microbial Influences in Inflammatory Bowel Diseases. Gastroenterology 2008; 134(2): 577–594.
28. Kump PK, Gröchenig H-P, Lackner S et al. Alteration of Intestinal Dysbiosis by Fecal Microbiota Transplantation Does not Induce Remission in Patients with Chronic Active Ulcerative Colitis. Inflamm Bowel Dis 2013; 19(10): 2155–2165.
29. Moayyedi P, Surette MG, Kim PT et al. Fecal Microbiota Transplantation Induces Remission in Patients with Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology 2015; 149(1): 102–109.
30. Gordon H, Harbord M. A patient with severe Crohn’s colitis responds to Faecal Microbiota Transplantation. J Crohns Colitis 2014; 8(3): 256–257.
31. Armougom F, Henry M, Vialettes B et al. Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and Methanogens in anorexic patients. PloS One 2009; 4(9): e7125. Dostupné z DOI: http://dx.doi.org/10.1371/journal.pone.0007125.
32. Qin J, Li Y, Cai Z et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012; 490(7418): 55–60.
33. Vrieze A, Van Nood E, Holleman F et al. Transfer of Intestinal Microbiota From Lean Donors Increases Insulin Sensitivity in Individuals With Metabolic Syndrome. Gastroenterology 2012; 143(4): 913–916. Erratum in Gastroenterology 2013; 144(1): 250.
34. Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology 2014; 146(6): 1513–1524.
35. Tuohy KM, Fava F, Viola R. “The way to a man’s heart is through his gut microbiota” – dietary pro- and prebiotics for the management of cardiovascular risk. Proc Nutr Soc 2014; 73(2): 172–185.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2016 Issue 2
Most read in this issue
- The patient complains of spinal pain or fatigue and weakness. How do I recognize whether their cause is spondylarthrosis, the patient’s age or multiple myeloma?
- Lead poisoning. A surprising cause of constipation, abdominal pain and anemia
- AT1-blockers in the treatment of hypertension: summary
- The rational diagnostic of cholangiocarcinoma